StreetAlpha.app
Home › Stocks › AUTL

Autolus Therapeutics plc (AUTL)

Healthcare
$0.91
▼ −7.38%
LAST CLOSE · NOV 20

Autolus Therapeutics develops and makes T cell therapies for cancer and autoimmune diseases, and sells AUCATZYL for leukemia. It last closed at $0.91 on Nov 20, down 7.38% on the day. The next earnings report for AUTL is expected around Fri, Mar 26, 2027. For the quarter ended Sep 2026, AUTL reported EPS of -$0.21 on revenue of $41.2M, with revenue up 94.6% from a year ago. Over its last 8 reports the stock moved an average of 8.9% the session after earnings. Over the last 12 months AUTL insiders bought $0 of stock on the open market and sold $16K, according to SEC Form 4 filings.

AI Auto Pilots
Is AUTL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AUTL.

Key Stats

Last 12 months
Results
Revenue
$137.4M
+168.8% vs a year ago
Net income
−$256.1M
−186.4% margin
EPS (diluted)
−$0.96
Free cash flow
−$180.2M
−131.1% margin
Valuation
Market cap
$241.7M
266.3M shares
P/E
–
No P/E while losing money
Price to sales
1.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$245.4M
At Sep 30
Shareholder equity
$27.4M
Shares outstanding
266.3M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $1.7M$1.7MFY2023FY2024: $10.1M$10.1MFY2024FY2025: $75.4M$75.4MFY2025

From AUTL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 26
Estimated date · Time not announced
Reported EPS
-$0.21
Quarter ended Sep 2026
Year ago EPS
-$0.30
Same quarter last year
Revenue
$41.2M
+94.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.09Dec '24Mar 2025: -$0.26Mar '25Jun 2025: -$0.18Jun '25Sep 2025: -$0.30Sep '25Dec 2025: -$0.34Dec '25Mar 2026: -$0.27Mar '26Jun 2026: -$0.15Jun '26Sep 2026: -$0.21Sep '26Latest -$0.21
Revenue by quarter
Dec 2024: $29,000Dec '24Mar 2025: $9.0MMar '25Jun 2025: $20.9MJun '25Sep 2025: $21.2MSep '25Dec 2025: $24.3MDec '25Mar 2026: $26.2MMar '26Jun 2026: $45.7MJun '26Sep 2026: $41.2MSep '26Latest $41.2M
How AUTL moved after its last 8 reports
Average move the session after a report ±8.9%
Nov 10, 2026Time not announced0.0%
Aug 11, 2026Time not announced+12.6%
May 14, 2026Time not announced−7.0%
Mar 27, 2026Time not announced−6.2%
Nov 12, 2025Time not announced−9.3%
Aug 12, 2025Time not announced−12.8%
May 8, 2025Time not announced+9.8%
Mar 20, 2025Time not announced−13.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AUTLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AUTL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AUTL

Technical Analysis

AUTL · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 43% below its 20 day and 76% below its 50 day average. It is 82% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 17), oversold. The nearest support is the 52 week low at $0.90, and the nearest resistance the Pivot at $0.93.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 11.4%/day
Key levels
$2.5852 week high+183.5%
$1.76100 day average+93.4%
$1.65200 day average+81.3%
$1.6050 day average+75.8%
$1.38Swing high (Nov 10)+51.6%
$1.3020 day average+42.9%
$0.96Pivot R1+5.5%
$0.93Pivot+2.2%
$0.91Last close
$0.9052 week low−1.1%
$0.88Pivot S1−3.3%
Indicators
RSI (14)16.78Oversold below 30Oversold
MACD-0.18Below its signal lineBearish
Stochastic2.4Near the bottom of its rangeOversold
ADX (14)51.4Strong downtrend
Williams %R-98.1Oversold below −80, overbought above −20Oversold
CCI (20)-155.2Oversold below −100, overbought above 100Oversold
Rate of change−29.1%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 11.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AUTL

What happened before

See how AUTL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AUTL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AUTL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AUTLHow many large options trades hit AUTL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AUTL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲44 buying vs 33 selling
  • ●Held by funds -0.3 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9184+8.3%
In funds' top 10330.0%
Held by funds49.3%49.6%−0.3 pts
New / increased16 / 289 / 27+22.2%
Reduced / sold out23 / 1021 / 10+6.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AUTL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AUTL Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$16K1 sale · 1 insider
2026-09 sold $16KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 2Cintia PiccinaU.S. CCO & Country Gen ManagerSale6,713$2.34$16K
Every insider buy and sale for AUTL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AUTL insider trades →

From SEC Form 4 filings by AUTL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AUTL is in one of them and how their past AUTL trades turned out.

AUTL in the AI portfolios
Loading…

AUTL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AUTL in an article yet. Here's the latest on the wider market.

AUTL in the news

About Autolus Therapeutics

Autolus Therapeutics is a biopharmaceutical company based in London, United Kingdom. It develops and manufactures cell therapies that reprogram a patient's own T cells so they can recognize and attack target cells. Its main product, AUCATZYL, is approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States and the United Kingdom. The company is also testing its therapy in other cancers and in autoimmune diseases such as lupus and multiple sclerosis.

Headquarters
London, United Kingdom